A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients
Phase 2
Active, not recruiting
- Conditions
- Sepsis
- Interventions
- Drug: STC314 Injection/STC314 Injection Placebo
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Grand Medical Pty Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06548854
- Locations
- 🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome
Phase 1
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Drug: STC314 injection or Placebo(rate=58.3 mg/hr)Drug: STC314 injection or Placebo(rate=87.5 mg/hr)
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Grand Medical Pty Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05000671
- Locations
- 🇨🇳
Wuhan Jinyintan Hospital, Wuhan, Hubei, China
🇨🇳Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇨🇳Wuhan Union Hospital, Wuhan, Hubei, China
A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Grand Medical Pty Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04880694
- Locations
- 🇧🇪
Onze-Lieve-Vrouwziekenhuis Aalst, VZW, Aalst, Belgium
🇧🇪Universitair Ziekenhuis Brussel, Brussel, Belgium
🇧🇪CHU Liège, Liège, Belgium
© Copyright 2025. All Rights Reserved by MedPath